S_q Treatment and survival rates of patients with non-small-cell lung cancer (NSCLC) were compared between three French Cancer Regisries (Calvados, Doubs, Tarn). The methodological issues in such comparisons are discunsed-The treatments for NSCLC differed betwen the regions: radiotherapy tended to be preferred in Calvados (73% vs 21.3% surgery), whereas surgery was more firquently employed in Doubs and Tarn (27.7% and 37% respectivdy al., 1988), although the adverse effects of chemotherapy have tnded to restrict its use in this application (Splinter, 1990) . Practitioners still lack effective treatment for a large number of lung tumours, which accounts for the diversity of strategies and the decision to withhold therapeutic treatment in numerous cases.
Lung (bronchus) cancer ranks first for both mortality and morbidity in men in Frnce (Hill et at., 1989; Benhamou et al., 1990) . Although its incidence is low in women, it is increasing, and is hikely to continue to do so in view of the increasing numbers of female smokers. The prognosis for this cancer is still extrmely poor and progress in suitable therapies is slow. Although there is a lack of consensus on the treatment of primary bronchial cancer, crrtain ruls are widely accepted. It is gneraly considered that 25-30% of non-small-cel lung cancer (NSCLC) can be treated by surgery, and that radiotherapy is beneficial in 30% of other cases with more advanced stages (Johnson et al., 1990) . Pallative thoracic radiotherapy is also employed to reduce the major symptoms caused by tumoral extension (MRC Lung Cancer Working Party, 1991) . A survival benefit of chemotherapy has been demonstrated in a randomised trial (Rapp et al., 1988) , although the adverse effects of chemotherapy have tnded to restrict its use in this application (Splinter, 1990) . Practitioners still lack effective treatment for a large number of lung tumours, which accounts for the diversity of strategies and the decision to withhold therapeutic treatment in numerous cases.
Although hospital sries have indicated an increase in therapeutic efficacy, this was not confirmed in a recent study from the Scottish Cancer Registry, which failed to observe any overall improvement in the prognosis of lung cancer over the last 25 years (Black et al., 1993) . The therapeutic progress observed in hospital series may be attributed to the selection of the patients who are given the potentially more efficacious therapy. Population-based data are therefore of particular interest, although they do pose problems of comparability. In the present study we analysed data from three populationbased cancer registries in an attempt to discern differences in treatment and overall survival from lung ancer in three disti regions of France. (Gulliford et al., 1993 ). An American study showed that this absence was even more frequent for lung cancer than for other cancers, such as those of breast or colon (Feigl et al., 1988) . Although this does have some influence on the interpretation of our results, we thought it unlikely that there would be large differences in the distribution of the clinical stages at the time of diagnosis between the three regions.
The observed distribution of pathological types is consistent with that seen in other populations. Among lung cancers, the proportion of squamous cell carcinoma ranges from 45% to 50% and that of adenocarcinoma from 16% to 25% in the different European registries (Lutz et al., 1988; Registre Genevois des Tumeurs, 1989; Zanetti et al., 1992) . The variations in the proportions of adenocarcinomas can be explained by the inclusion in the lung cancer category of different proportions of cases with primary or doubtful secondary tumours. There was a marked regional difference in trtment, which also emerged from a previous study on diagnostic attitude and regular treatment of lung cancer in 70 hospital teams (Mazover et al., 1989) . In our study, the differences in therapies between regons cannot be accounted for by differences in age, gender and morphology. The largest differences in treatment were observed between Calvados and Tarn, with Doubs being in the intermediate position.
Radiotherapy was frequently employed in Calvados, often as sole treatment and in relatively few cases in combination with surgery. This contrasted with the situation in Tarn, where NSCLCs were generally treated surgically. The difference in therapeutic strategy has an influence on the number of nontreated patients. The fact that radiotherapy has fewer contraindications than surgery means that it can be employed on a larger proportion of patients, especially the eklerly, and may account for the smaler proportion of untreated patients in Calvados compared with Tarn. The regional differences in treatment strategies may be explained by differences in the availability of services. For example, Calvados has a comprehensive cancer centre where radiotherapy is one of its specialties, whereas in Tarn many patients are treated in private clinics lacing specialised services.
There have been few detailed stui on lung cancer survival based on population data (Watkin et al., 1990; Sant et al., 1992) . Most of the data on pathological types and treatments come from hospital data and the results of therapeutic trials, which are not readily extrapolated to the whole population of patients in a given region.
A more favourable prognosis for women has been noted by some cancer registries (Registre Genevois des Tumeurs, 1989; National Cancer Institute, 1991) , although this has not been reported by other authors (McDuffie et al., 1991; Sant et al., 1992 (Kant et al., 1992) .
Despite the differences in treatment, espeialy in the use of surgery, there was no overall difference in survival rates between the three regions. The prognostic value of surgery differed from one region to another, and its effectiveness appeared to be higher in the regions where it was least used. The greater use of surgery in Tarn is explained by the choice of surgical treatment for patients with an a priori poor prognosis. The prognosis for both surgically and nonsurgically treated patients was thus worse in Tarn than in Calvados (Figure 1) (Feinstein et al., 1985) . Treatment-adjusted analysis can erroneously predict a higher survival in areas (or groups) where the indications are the most selective, whereas the results for the overall population are identical in both areas.
Coecmo.
This study confirms the poor prognosis of lung cancer and the marked difference between patients who benefit from surgery and those who do not. We found a considerable diversity in the treatments offered between regions, and differences in the percentage of cases receiving no therapeutic treatment. These differences had no influence on survival rate, however, which was similar in the three regions. These observations lend support to the idea that prognostic differences between hospital series can be accounted for in terms of differences in the selection of patients. This highlights the utility of population data for an exact representation of lung cancer treatments, but also shows the inherent limitations of our data. To interpret the data in more detail and identify selection effects, registries need to record more comprehensive data, especially the clinical stage of the tumour at diagnosis. This will in turn require a closer collaboration with the relevant clinicians as this information is often not included in the hospital records.
